Table 3.
Demographics and clinical characteristics in 116 donors with LP categorized according to MDS-PD criteria 19
| Established PD donors with LP | Not PD or probable PD donors with LP | |
|---|---|---|
| N | 71 | 45 |
| Sex M, n (%) | 38 (54%) | 33 (73%)* |
| Age at onset y, mean ± SD (range) | 60 ± 11 (32–78) | 63 ± 12 (40–84) |
| Age at death y, mean ± SD (range) | 77 ± 8 (56–90) | 76 ± 9 (56–90) |
| Disease duration y, mean ± SD (range) | 17 ± 8 (4–42) | 13 ± 6 (3–31)** |
| Dementia, n (%) | 37 (52%) | 24 (53%) |
| Duration of dementia y, mean ± SD (range) | 4 ± 3 (0–12) | 4 ± 2 (0–7) |
| Visual hallucinations, n/N (%) | 48/61 (79%) | 25/36 (69%) |
| Rest tremor, n/N (%) | 62/70 (89%) | 31/42 (74%)* |
| Clear response to dopaminergic therapy, n/N (%) | 68/71 (96%) | 26/41 (63%)*** |
| Positive family history of parkinsonism, n/N (%) | 13/34 (38%) | 14/26 (54%) |
| APOE ε4 alleles, n/N (%) | ||
| 0 | 28/45 (62%) | 16/24 (67%) |
| 1 | 15/45 (33%) | 8/24 (33%) |
| 2 | 2/45 (4%) | 0/24 (0%) |
P-values are shown for comparisons between ‘established PD’ and ‘not PD’ combined with ‘probable PD’ donors with LP using t-tests for continuous variables and chi-square tests for categorical variables. * p < 0.05; ** p < 0.01; *** p < 0.001